-
11.发明公开
公开(公告)号：EP2862577A1
公开(公告)日：2015-04-22
申请号：EP13761384.0
申请日：2013-03-08
CPC分类号： C07K14/575 , A61K38/2214 , C07K14/60
摘要： The present invention relates to the use of obestatin, or to the nucleotide sequence that codes for same, as an in vitro myogenic agent, and for the production of a drug for muscle regeneration, preferably for musculoskeletal regeneration, thus being useful in the treatment and/or prevention of degenerative or genetic diseases or of lesions that present with muscle damage.
摘要翻译： 本发明涉及肥胖抑制剂，或编码与体外成肌剂相同的核苷酸序列的用途，以及用于生产用于肌肉再生的药物，优选用于肌肉骨骼再生，因此可用于治疗和 /或预防退行性或遗传性疾病或伴有肌肉损伤的病变。
-
公开(公告)号：EP0437622A1
公开(公告)日：1991-07-24
申请号：EP90910190.9
申请日：1990-07-06
IPC分类号： A61K37/24
CPC分类号： A61K38/2214 , A61K47/02 , A61K47/183 , A61K47/26 , A61K47/36 , A61K47/42
摘要： A stable motilin preparation which comprises motilin and at least one pharmaceutically acceptable stabilizer selected from the group consisting of sugars, amino acids, inorganic salts, and proteins.
摘要翻译： 一种稳定的胃动素制剂，其包含胃动素和选自由糖，氨基酸，无机盐和蛋白质组成的组中的至少一种药学上可接受的稳定剂。
-
公开(公告)号：EP0369437A3
公开(公告)日：1990-12-12
申请号：EP89121162.5
申请日：1989-11-15
发明人： Masada, Tomoaki , Ueno, Yasuhiko , Hayakawa, Eiji , Naganuma, Hirotake , Terajima, Mitsuru , Kuroda, Tokuyuki , Shuto, Katsuichi , Ichikawa, Shunji
CPC分类号： A61K9/02 , A61K38/2214
摘要： A motilin preparation in the form of a rectal supporitory containing motilin together with a pH controller capable of adjusting the pH value of the intrarectal fluid to 8.0 to 10.0, which is highly useful as a rectal suppository.
-
14.发明公开COMPOSITION FOR TRANSNASAL ADMINISTRATION AND METHOD FOR PRODUCING SAME 有权ZUSAMMENSETZUNG ZUR TRANSNASALEN VERABREICHUNG UND HERSTELLUNGSVERFAHRENDAFÜR
公开(公告)号：EP2548566A1
公开(公告)日：2013-01-23
申请号：EP11756447.6
申请日：2011-03-18
发明人： MATSUMOTO, Masaru , TAKEDA, Shuji , NOBORI, Kyohei
CPC分类号： A61K9/0043 , A61K9/008 , A61K9/1652 , A61K9/4866 , A61K38/2214 , A61K38/2242 , A61K38/25 , A61K38/29
摘要： The invention provides a powdered composition for nasal administration, comprising a physiologically active peptide and cellulose acetate as the base, and having excellent nasal absorption for physiologically active peptides.
摘要翻译： 本发明提供了一种用于鼻腔给药的粉末状组合物，其包含生理活性肽和乙酸纤维素作为碱，并且对于生理活性肽具有优异的鼻吸收性。
-
15.发明公开
公开(公告)号：EP2174660A4
公开(公告)日：2011-02-16
申请号：EP08790688
申请日：2008-06-27
发明人： KONDOH MASUO , UCHIDA HIROSHI , HANADA TAKESHI , HOSHINO MASATO
CPC分类号： A61K38/29 , A61K9/0019 , A61K9/0043 , A61K9/0073 , A61K38/164 , A61K38/2214 , A61K38/25 , A61K47/42 , A61K2300/00
-
16.发明公开
公开(公告)号：EP2210612A2
公开(公告)日：2010-07-28
申请号：EP10001568.4
申请日：2004-06-18
申请人： Tranzyme Pharma Inc.
发明人： Marsault, Eric , Benakli, Kamel , Peterson, Mark , Beaubien, Sylvie , St-Louis, Carl , Ouellet, Luc , Beauchemin, Sophie , Hoveyda, Hamid
IPC分类号： A61K38/22 , C07K5/08 , C07C13/00 , C07C15/00 , C07D213/00
CPC分类号： C07C213/08 , A61K38/12 , A61K38/2214 , C07C41/18 , C07C67/343 , C07D273/00 , C07D413/06 , C07D498/04 , C07K5/0812 , C07K5/0821 , C07K5/0827
摘要： The invention provides a first group of intermediates useful in the manufacture of conformationally-defined macrocyclic compounds, a method for making some of these and a second group of intermediate compounds prepared in this method, use of the first group of intermediates in the manufacture of conformationally-defined macrocyclic compounds and a method of so manufacturing, and conformationally-defined macrocyclic compounds made from the first group of intermediates.
摘要翻译： 本发明提供了可用于制造构象定义的大环化合物的第一组中间体，用于制备其中一些的方法和在该方法中制备的第二组中间体化合物，第一组中间体在制造构象中的用途 定义的大环化合物和由第一组中间体制备的方法，以及构象定义的大环化合物。
-
公开(公告)号：EP1633774B1
公开(公告)日：2010-02-17
申请号：EP04737852.6
申请日：2004-06-18
申请人： Tranzyme Pharma Inc.
发明人： FRASER, Graeme , MARSAULT, Eric , PETERSON, Mark , HOVEYDA, Hamid , BEAUBIEN, Sylvie , BENAKLI, Kamel , DEZIEL, Robert
CPC分类号： C07C213/08 , A61K38/12 , A61K38/2214 , C07C41/18 , C07C67/343 , C07D273/00 , C07D413/06 , C07D498/04 , C07K5/0812 , C07K5/0821 , C07K5/0827
摘要： The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
摘要翻译： 本发明涉及式（I）的新型大环化合物及其药学上可接受的盐，水合物或溶剂化物：其中R 1，R 2，R 3，R 4，R 5，R 6，n1，m，p Z1，Z2和Z3如 在说明书中描述。 本发明还涉及式（I）化合物，其是胃动素受体的拮抗剂并且可用于治疗与该受体相关的病症并伴有或伴随有运动功能障碍。
-
公开(公告)号：EP1633774A1
公开(公告)日：2006-03-15
申请号：EP04737852.6
申请日：2004-06-18
申请人： Tranzyme Pharma Inc.
发明人： FRASER, Graeme , MARSAULT, Eric , PETERSON, Mark , HOVEYDA, Hamid , BEAUBIEN, Sylvie , BENAKLI, Kamel , DEZIEL, Robert
CPC分类号： C07C213/08 , A61K38/12 , A61K38/2214 , C07C41/18 , C07C67/343 , C07D273/00 , C07D413/06 , C07D498/04 , C07K5/0812 , C07K5/0821 , C07K5/0827
摘要： The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
-
19.发明公开
公开(公告)号：EP0508435A3
公开(公告)日：1993-04-07
申请号：EP92106184.2
申请日：1992-04-09
发明人： Sawai, Kiichi, c/o Sanwa Kagaku Kenkyusho Co., Ltd , Kurono, Masayasu, c/o Sanwa Kagaku Kenkyusho , Kondo, Yasuaki, c/o Sanwa Kagaku Kenkyusho Co. Ltd , Sato, Makoto, c/o Sanwa Kagaku Kenkyusho Co., Ltd. , Kouzaki, Toshiyuki, c/o Sanwa Kagaku Kenkyusho
CPC分类号： A61K38/2214
摘要： There is disclosed a pharmaceutical composition of stabilized [Leu¹³]-motilin-Hse. The composition comprises at least one of organic acids and salts thereof, as a first stabilizer, and pH thereof is adjusted in a range of 5.5 - 8.0. The composition may contain at least one of substances selected from saccharides, amino acids, proteins and salts thereof, as a second stabilizer. Conversion of [Leu¹³]-motilin-Hse into [Leu¹³]-motilin-Hse-lactone is suppressed by increasing pH value and deamidization in asparagine residue at 19-position is suppressed by the presence of the organic acid or salt thereof.
-
20.发明公开Pharmaceutical composition of stabilized [Leu 13]-motilin-Hse 失效Pharmazeutische Zusammensetzung von stableisiertem [Leu 13] -Motilin-Hse。
公开(公告)号：EP0508435A2
公开(公告)日：1992-10-14
申请号：EP92106184.2
申请日：1992-04-09
发明人： Sawai, Kiichi, c/o Sanwa Kagaku Kenkyusho Co., Ltd , Kurono, Masayasu, c/o Sanwa Kagaku Kenkyusho , Kondo, Yasuaki, c/o Sanwa Kagaku Kenkyusho Co. Ltd , Sato, Makoto, c/o Sanwa Kagaku Kenkyusho Co., Ltd. , Kouzaki, Toshiyuki, c/o Sanwa Kagaku Kenkyusho
CPC分类号： A61K38/2214
摘要： There is disclosed a pharmaceutical composition of stabilized [Leu¹³]-motilin-Hse. The composition comprises at least one of organic acids and salts thereof, as a first stabilizer, and pH thereof is adjusted in a range of 5.5 - 8.0. The composition may contain at least one of substances selected from saccharides, amino acids, proteins and salts thereof, as a second stabilizer. Conversion of [Leu¹³]-motilin-Hse into [Leu¹³]-motilin-Hse-lactone is suppressed by increasing pH value and deamidization in asparagine residue at 19-position is suppressed by the presence of the organic acid or salt thereof.
摘要翻译： 公开了稳定的[Leu 1] - 胃动素-Hse的药物组合物。 该组合物包含至少一种有机酸及其盐作为第一稳定剂，其pH调节在5.5-8.0的范围内。 该组合物可以含有选自糖，氨基酸，蛋白质和盐的至少一种物质作为第二稳定剂。 通过增加pH值可以抑制[Leu <1> 3] - 胃动素-He转化为[Leu 1] - - 胃动素-Hse-内酯，并且在19位的天冬酰胺残基中的脱酰胺被抑制 有机酸或其盐的存在。
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.022 秒)
